Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Vera Therapeutics, Inc.

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases that improve patients’ lives.

We’re #hiring! #Joinourteam and take part in our mission to improve the standard of care for patients with serious immunological diseases.
Learn about our open positions here: https://lnkd.in/d2-8KHTC 

Today we announced our Q3 business update and financial results. Read the full release here: https://lnkd.in/df4BxFuY

Dr. Richard Lafayette, MD, FACP, spoke with HCPLive about the additional week 36 analyses from our ORIGIN Phase 2b clinical trial in #IgAN presented at ASN Kidney Week 2023. Watch the interview here: https://lnkd.in/d8eauakC
#kidneywk #IgANephropathy

Today we're presenting two posters with new week 36 analyses from our Phase 2b ORIGIN trial in #IgANephropathy at American Society of Nephrology Kidney Week: https://lnkd.in/dZtKAfQX
Be sure to stop by our posters SA-PO884 and SA-PO887 and visit us at booth 2321! 
#Kidneywk

We’re live at American Society of Nephrology Kidney Week 2023! Come to booth #2321 to learn about our research in #IgANephropathy. And don’t miss our poster presentations on Saturday: https://lnkd.in/dZpvugVK
#kidneywk

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	342K -	909K 165.79%	1.39M 52.37%	11.99M 765.78%	11.12M 7.28%
accumulated other comprehensive income loss			-83.75M -	-224K 99.73%	251K 212.05%
cash and cash equivalents	3.19M -	53.65M 1,579.31%	79.67M 48.50%	114.65M 43.90%	160.72M 40.18%
cash and short term investments	3.19M -	53.65M 1,579.31%	79.67M 48.50%	114.65M 43.90%	160.72M 40.18%
common stock			21K -	28K 33.33%	44K 57.14%
deferred revenue	376K -	533K 41.76%
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory		472K -
long term debt	10K -		4.92M -	28.64M 481.78%	49.88M 74.15%
long term investments			867K -	58K 93.31%	11K 81.03%
net debt	-3.06M -	-53.65M 1,651.62%	-74.75M 39.33%	-83.37M 11.53%	-107.01M 28.36%
net receivables		52K -
other assets					1 -
other current assets	4K -	83K 1,975%	2.86M 3,349.40%	11.04M 285.78%	11.31M 2.37%
other current liabilities	220K -	962K 337.27%	6.30M 555.41%	10.96M 73.89%	8.75M 20.20%
other liabilities
other non current assets	422K -	293K 30.57%	344K 17.41%	506K 47.09%	563.00K 11.26%
other non current liabilities	40.86M -	141.50M 246.30%	1.54M 98.91%	286K 81.46%	1.68M 487.76%
othertotal stockholders equity	1.49M -	2.10M 41.25%	193.63M 9,124.73%	290.22M 49.88%	410.49M 41.44%
preferred stock			83.75M -
property plant equipment net	1.39M -			5.17M -	2.95M 42.99%
retained earnings	-38.03M -	-91.45M 140.43%	-124.06M 35.66%	-213.11M 71.79%	-309.10M 45.04%
short term debt	122K -	2K 98.36%		2.65M -	2.44M 7.90%
short term investments				71.19M -
tax assets
tax payables
total assets	5.38M -	54.55M 913.83%	83.75M 53.51%	131.44M 56.94%	175.55M 33.56%
total current assets	3.56M -	54.26M 1,422.05%	82.54M 52.11%	125.70M 52.29%	172.02M 36.85%
total current liabilities	1.06M -	2.41M 126.98%	7.69M 219.62%	25.60M 232.90%	22.30M 12.88%
total debt	132K -	2K 98.48%	4.92M 246,050%	31.29M 535.51%	53.71M 71.67%
total investments			867K -	71.25M 8,118.22%	11K 99.98%
total liabilities	41.93M -	143.90M 243.20%	14.16M 90.16%	54.53M 285.19%	73.86M 35.46%
total liabilities and stockholders equity	5.38M -	54.55M 913.83%	83.75M 53.51%	131.44M 56.94%	175.55M 33.56%
total non current assets	1.82M -	293K 83.87%	1.21M 313.31%	5.74M 373.74%	3.52M 38.59%
total non current liabilities	40.87M -	141.50M 246.22%	6.47M 95.43%	28.93M 347.37%	51.56M 78.23%
total stockholders equity	-36.55M -	-89.35M 144.47%	69.59M 177.89%	76.91M 10.51%	101.69M 32.22%

COM:VERATX

Vera Therapeutics, Inc.

Last Close

45.75

21/11 21:00

Market Cap

2.00B

Beta: -

Volume Today

401.03K

Avg: -

Preview